Study to Explore the Efficacy and Safety of BIO89-100 (Pegozafermin) in Participants With Severe Hypertriglyceridemia
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Explore the Efficacy and Safety of BIO89-100 in Subjects With Severe Hypertriglyceridemia
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Pardubice, Czechia, 530 02
- 89bio Clinical Study Site
-
Prague, Czechia, 100 00
- 89bio Clinical Study Site
-
Prague, Czechia, 150 00
- 89bio Clinical Study Site
-
Prague, Czechia, 158 00
- 89bio Clinical Study Site
-
Praha 4, Czechia, 14021
- 89bio Clinical Study Site
-
-
-
-
-
Baja, Hungary
- 89bio Clinical Study Site
-
Budapest, Hungary, 1032
- 89bio Clinical Study Site
-
Békéscsaba, Hungary, 5600
- 89bio Clinical Study Site
-
Debrecen, Hungary, 4032
- 89bio Clinical Study Site
-
-
Borsod-Abauj-Zemplen
-
Miskolc, Borsod-Abauj-Zemplen, Hungary, 3529
- 89bio Clinical Study Site
-
-
-
-
-
Białystok, Poland, 15-351
- 89bio Clinical Study Site
-
Białystok, Poland, 15-879
- 89bio Clinical Study Site
-
Lodz, Poland, 93-338
- 89bio Clinical Study Site
-
Oswiecim, Poland, 32-600
- 89bio Clinical Study Site
-
Rzeszów, Poland, 35-055
- 89bio Clinical Study Site
-
Toruń, Poland, 87-100
- 89bio Clinical Study Site
-
-
-
-
California
-
La Mesa, California, United States, 91942
- 89bio Clinical Study Site
-
San Francisco, California, United States, 94158
- 89bio Clinical Study Site
-
-
Florida
-
Clearwater, Florida, United States, 33756
- 89bio Clinical Study Site
-
Greenacres City, Florida, United States, 33467
- 89bio Clinical Study Site
-
Jacksonville, Florida, United States, 32205
- 89bio Clinical Study Site
-
Miami, Florida, United States, 33125
- 89bio Clinical Study Site
-
Miami, Florida, United States, 33135
- 89bio Clinical Study Site
-
Miami Lakes, Florida, United States, 33014
- 89bio Clinical Study Site
-
Miami Lakes, Florida, United States, 33016
- 89bio Clinical Study Site
-
North Miami Beach, Florida, United States, 33162
- 89bio Clinical Study Site
-
Orlando, Florida, United States, 32825
- 89bio Clinical Study Site
-
Tampa, Florida, United States, 33606
- 89bio Clinical Study Site
-
-
Georgia
-
Lawrenceville, Georgia, United States, 30044
- 89bio Clinical Study Site
-
-
Illinois
-
Quincy, Illinois, United States, 62301
- 89bio Clinical Study Site
-
Wauconda, Illinois, United States, 60084
- 89bio Clinical Study Site
-
-
Iowa
-
West Des Moines, Iowa, United States, 50266
- 89bio Clinical Study Site
-
-
Kentucky
-
Louisville, Kentucky, United States, 40213
- 89bio Clinical Study Site
-
-
Mississippi
-
Olive Branch, Mississippi, United States, 38654
- 89bio Clinical Study Site
-
-
New York
-
Albany, New York, United States, 12203
- 89bio Clinical Study Site
-
-
North Carolina
-
Greensboro, North Carolina, United States, 27408
- 89bio Clinical Study Site
-
Morganton, North Carolina, United States, 28655
- 89bio Clinical Study Site
-
-
Ohio
-
Marion, Ohio, United States, 43303
- 89bio Clinical Study Site
-
-
South Carolina
-
Summerville, South Carolina, United States, 29435
- 89bio Clinical Study Site
-
-
Tennessee
-
Chattanooga, Tennessee, United States, 37421
- 89bio Clinical Study Site
-
Kingsport, Tennessee, United States, 37660
- 89bio Clinical Study Site
-
-
Texas
-
Austin, Texas, United States, 78705
- 89bio Clinical Study Site
-
Dallas, Texas, United States, 75204
- 89bio Clinical Study Site
-
Dallas, Texas, United States, 77365
- 89bio Clinical Study Site
-
Houston, Texas, United States, 77089
- 89bio Clinical Study Site
-
Lampasas, Texas, United States, 76550
- 89bio Clinical Study Site
-
Magnolia, Texas, United States, 77355
- 89bio Clinical Study Site
-
-
Virginia
-
Manassas, Virginia, United States, 20110
- 89bio Clinical Study Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male or female age ≥21 to ≤75 years.
- Screening fasting triglyceride ≥500 milligrams (mg)/deciliters (dL) and ≤2000 mg/dL.
- Willing to maintain current eating and exercise habits from time of signing the informed consent and for the duration of the study.
- Participants could be taking statins and/or prescription fish oil as background therapy or not be taking any background therapy.
- Magnetic resonance imaging - whole liver proton density fat fraction (MRI-PDFF) of ≥6% for participants screened for the Fibrate Expansion cohort.
Exclusion Criteria:
- Uncontrolled or newly diagnosed hypertension.
- Body mass index >45 kilograms (kg)/meters squared (m^2).
- Receiving niacin, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, or supplements that could lower lipid levels.
- Type 1 diabetes mellitus.
- Diagnosis of Type 2 diabetes mellitus <6 months prior to screening.
- History of malignancy within 5 years prior to screening.
- Participants with known lipoprotein lipase impairment or deficiency (Fredrickson Type 1), apolipoprotein C-II deficiency, or familial dysbetalipoproteinemia (Fredrickson Type 3).
- Clinically or otherwise documented cardiovascular or cerebrovascular disease.
- Weight change ≥5% in 3 months prior to first screening visit or weight change ≥5% during screening or planning to try to lose weight during conduct of study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Pegozafermin 9 mg QW
Participants received pegozafermin 9 mg QW as an SC injection for 8 weeks in the Main Study cohort.
|
Subcutaneous injection
Other Names:
|
|
Experimental: Pegozafermin 18 mg QW
Participants received pegozafermin 18 mg QW as an SC injection for 8 weeks in the Main Study cohort.
|
Subcutaneous injection
Other Names:
|
|
Experimental: Pegozafermin 27 mg QW
Participants received pegozafermin 27 mg QW as an SC injection for 8 weeks in the Main Study cohort or Fibrate Expansion cohort.
Main Study and Fibrate Expansion pegozafermin 27 mg QW groups were pooled together due to low sample size in the expansion cohort.
|
Subcutaneous injection
Other Names:
|
|
Experimental: Pegozafermin 36 mg Q2W
Participants received pegozafermin 36 mg Q2W as an SC injection for 8 weeks in the Main Study cohort.
|
Subcutaneous injection
Other Names:
|
|
Placebo Comparator: Placebo
Matching placebo was injected at matching frequency per assigned cohort for 8 weeks in the Main Study cohort or Fibrate Expansion cohort.
Main Study and Fibrate Expansion placebo groups were pooled together due to low sample size in the expansion cohort.
|
Matching placebo
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Percent Change From Baseline to Week 8 in Serum Triglyceride (TG)
Time Frame: Baseline, Week 8
|
Baseline, Week 8
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Participants Who Achieved TG <500 mg/dL at Week 8
Time Frame: Week 8
|
Week 8
|
|
|
Percent Change From Baseline to Week 8 in Non-high-density Lipoprotein Cholesterol (Non-HDL-C), Apolipoprotein B100 (ApoB), Low-density Lipoprotein Cholesterol (LDL-C), and High-density Lipoprotein Cholesterol (HDL-C)
Time Frame: Baseline, Week 8
|
Least Squares Means were calculated using mixed-model repeated measures (MMRM).
|
Baseline, Week 8
|
|
Percent Change From Baseline to Week 8 in Very Low-density Lipoprotein Cholesterol (VLDL-C) and VLDL-TG
Time Frame: Baseline, Week 8
|
Baseline, Week 8
|
|
|
Percent Change in Baseline to Week 8 in Fasting Plasma Glucose, Adiponectin, and Body Weight
Time Frame: Baseline, Week 8
|
Least Squares Mean was calculated using MMRM.
|
Baseline, Week 8
|
|
Percent Change From Baseline to Week 8 in Liver Fat as Assessed by Magnetic Resonance Imaging - Whole Liver Proton Density Fat Fraction (MRI-PDFF)
Time Frame: Baseline, Week 8
|
Least Squares Mean was calculated using analysis of covariance (ANCOVA).
|
Baseline, Week 8
|
|
Percent Change From Baseline to Week 8 in High-sensitivity C-reactive Protein (hsCRP)
Time Frame: Baseline, Week 8
|
Baseline, Week 8
|
|
|
Percent Change From Baseline to Week 8 in Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST)
Time Frame: Baseline, Week 8
|
Least Squares Mean was calculated using MMRM.
|
Baseline, Week 8
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- BIO89-100-221
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.